-
Fetched: December 2nd, 2024, 3:00am UTC
Conditions:
Recurrent
Adenoid
Cystic
Carcinoma
of
the
Oral
Cavity;
Recurrent
Mucoepidermoid
Carcinoma
of
the
Oral
Cavity;
Recurrent
Squamous
Cell
Carcinoma
of
the
Hypopharynx;
Recurrent
Squamous
Cell
Carcinoma
of
the
Larynx;
Recurrent
Squamous
Cell
Carcinoma
of
the
Lip
and
Oral
Cavity;
Recurrent
Verrucous
Carcinoma
of
the
Larynx;
Recurrent
Verrucous
Carcinoma
of
the
Oral
Cavity;
Stage
0
Hypopharyngeal
Cancer;
Stage
0
Laryngeal
Cancer;
Stage
0
Lip
and
Oral
Cavity
Cancer;
Stage
I
Adenoid
Cystic
Carcinoma
of
the
Oral
Cavity;
Stage
I
Mucoepidermoid
Carcinoma
of
the
Oral
Cavity;
Stage
I
Squamous
Cell
Carcinoma
of
the
Hypopharynx;
Stage
I
Squamous
Cell
Carcinoma
of
the
Larynx;
Stage
I
Squamous
Cell
Carcinoma
of
the
Lip
and
Oral
Cavity;
Stage
I
Verrucous
Carcinoma
of
the
Larynx;
Stage
I
Verrucous
Carcinoma
of
the
Oral
Cavity;
Stage
II
Adenoid
Cystic
Carcinoma
of
the
Oral
Cavity;
Stage
II
Mucoepidermoid
Carcinoma
of
the
Oral
Cavity;
Stage
II
Squamous
Cell
Carcinoma
of
the
Hypopharynx;
Stage
II
Squamous
Cell
Carcinoma
of
the
Larynx;
Stage
II
Squamous
Cell
Carcinoma
of
the
Lip
and
Oral
Cavity;
Stage
II
Verrucous
Carcinoma
of
the
Larynx;
Stage
II
Verrucous
Carcinoma
of
the
Oral
Cavity;
Stage
III
Adenoid
Cystic
Carcinoma
of
the
Oral
Cavity;
Stage
III
Mucoepidermoid
Carcinoma
of
the
Oral
Cavity;
Stage
III
Squamous
Cell
Carcinoma
of
the
Hypopharynx;
Stage
III
Squamous
Cell
Carcinoma
of
the
Larynx;
Stage
III
Squamous
Cell
Carcinoma
of
the
Lip
and
Oral
Cavity;
Stage
III
Verrucous
Carcinoma
of
the
Larynx;
Stage
III
Verrucous
Carcinoma
of
the
Oral
Cavity;
Stage
IV
Squamous
Cell
Carcinoma
of
the
Hypopharynx;
Stage
IVA
Adenoid
Cystic
Carcinoma
of
the
Oral
Cavity;
Stage
IVA
Mucoepidermoid
Carcinoma
of
the
Oral
Cavity;
Stage
IVA
Squamous
Cell
Carcinoma
of
the
Larynx;
Stage
IVA
Squamous
Cell
Carcinoma
of
the
Lip
and
Oral
Cavity;
Stage
IVA
Verrucous
Carcinoma
of
the
Larynx;
Stage
IVA
Verrucous
Carcinoma
of
the
Oral
Cavity;
Stage
IVB
Adenoid
Cystic
Carcinoma
of
the
Oral
Cavity;
Stage
IVB
Mucoepidermoid
Carcinoma
of
the
Oral
Cavity;
Stage
IVB
Squamous
Cell
Carcinoma
of
the
Larynx;
Stage
IVB
Squamous
Cell
Carcinoma
of
the
Lip
and
Oral
Cavity;
Stage
IVB
Verrucous
Carcinoma
of
the
Larynx;
Stage
IVB
Verrucous
Carcinoma
of
the
Oral
Cavity;
Stage
IVC
Adenoid
Cystic
Carcinoma
of
the
Oral
Cavity;
Stage
IVC
Mucoepidermoid
Carcinoma
of
the
Oral
Cavity;
Stage
IVC
Squamous
Cell
Carcinoma
of
the
Larynx;
Stage
IVC
Squamous
Cell
Carcinoma
of
the
Lip
and
Oral
Cavity;
Stage
IVC
Verrucous
Carcinoma
of
the
Larynx;
Stage
IVC
Verrucous
Carcinoma
of
the
Oral
Cavity;
Tongue
Cancer
Interventions:
Procedure:
transoral
robotic
surgery;
Procedure:
quality
of
life
assessment
Sponsors:
Ohio
State
University
Comprehensive
Cancer
Center
Recruiting
-
Posted: October 14th, 2024, 11:00pm UTC
Conditions: Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor
Interventions: Drug: Nivolumab
Sponsors: Instituto do Cancer do Estado de São Paulo; Financiadora de Estudos e Projetos
Recruiting
-
Posted: August 2nd, 2024, 11:00pm UTC
Conditions: Cancer; Cystic Carcinomas, Adenoid; Soft-tissue Sarcomas; Rhabdomyosarcoma Pleomorphic; Sarcoma,Soft Tissue; Osteosarcomas; Chondrosarcoma, Grade 3; Chordoma; Angiosarcomas
Interventions: Other: Questionnaire
Sponsors: Hospices Civils de Lyon; Centre François Baclesse, Centre de lutte contre le cancer (CLCC)
Not yet recruiting
-
Posted: July 26th, 2024, 11:00pm UTC
Conditions: Metastatic Adenoid Cystic Carcinoma
Interventions: Procedure: Computed Tomography; Other: Electronic Health Record Review; Drug: Ga-68 PSMA-11; Procedure: Positron Emission Tomography
Sponsors: Mayo Clinic
Enrolling by invitation
-
Posted: June 17th, 2024, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma; Colorectal Cancer
Interventions: Drug: RGT-61159
Sponsors: Rgenta Therapeutics Inc
Recruiting
-
Posted: March 21st, 2024, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: 177Lu-PNT2002
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Adenoid Cystic Carcinoma Research Foundation; Progenics Pharmaceuticals, Inc.
Not yet recruiting
-
Posted: January 10th, 2024, 1:00am UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: Lutetium (177Lu) vipivotide tetraxetan
Sponsors: Maria Sklodowska-Curie National Research Institute of Oncology
Not yet recruiting
-
Posted: November 7th, 2023, 1:00am UTC
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: REM-422
Sponsors: Remix Therapeutics
Recruiting
-
Posted: July 5th, 2023, 11:00pm UTC
Conditions:
Adenoid
Cystic
Carcinoma
of
the
Head
and
Neck
Interventions:
Drug:
OBT076;
Drug:
Balstilimab
Sponsors:
Groupe
Oncologie
Radiotherapie
Tete
et
Cou
Completed
-
Posted: March 20th, 2023, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: CB-103; Drug: Abemaciclib; Drug: Lenvatinib
Sponsors: Glenn J. Hanna; Adenoid Cystic Carcinoma Research Foundation; Cellestia Biotech AG
Active, not recruiting
-
Posted: February 17th, 2023, 1:00am UTC
Conditions: Carcinoma, Adenoid Cystic; Head and Neck Cancer
Interventions: Radiation: simultaneous integrated boost of carbon ions radiation therapy
Sponsors: CNAO National Center of Oncological Hadrontherapy
Recruiting
-
Posted: October 17th, 2022, 11:00pm UTC
Conditions: Salivary Gland Tumor; Rare Malignant Neoplasm
Interventions: Diagnostic Test: 68-Ga PSMA PET scan
Sponsors: National Cancer Centre, Singapore
Active, not recruiting
-
Posted: May 17th, 2022, 11:00pm UTC
Conditions: Triple Negative Breast Cancer; Breast Cancer; Endometrial Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cavity Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: XMT-1660
Sponsors: Mersana Therapeutics
Recruiting
-
Posted: January 18th, 2022, 1:00am UTC
Conditions:
Ovarian
Neoplasms;
Peritoneal
Neoplasms;
Fallopian
Tube
Neoplasms;
Triple
Negative
Breast
Neoplasms;
HER2
Negative
Breast
Neoplasms;
Hormone
Receptor
Positive
Breast
Neoplasms;
Endometrial
Neoplasms;
Carcinoma,
Non-Small-Cell
Lung;
Cholangiocarcinoma;
Gallbladder
Carcinoma;
Adenoid
Cystic
Carcinoma
Interventions:
Drug:
SGN-B7H4V;
Drug:
Pembrolizumab
Sponsors:
Seagen
Inc.
Recruiting
-
Posted: October 12th, 2021, 11:00pm UTC
Conditions: Salivary Gland Cancer
Interventions: Drug: Amivantamab
Sponsors: Trisha Wise-Draper
Recruiting
-
Posted: July 22nd, 2021, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Drug: AL101; Procedure: Therapeutic Conventional Surgery
Sponsors: M.D. Anderson Cancer Center
Recruiting
-
Posted: May 20th, 2021, 11:00pm UTC
Conditions: Metastatic Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Stage IV Major Salivary Gland Cancer AJCC v8; Adenoid Cystic Carcinoma
Interventions: Biological: Pembrolizumab; Drug: Pemetrexed Disodium; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Procedure: Magnetic Resonance Imaging; Procedure: PSMA PET Scan
Sponsors: Mayo Clinic
Recruiting
-
Posted: May 12th, 2021, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Other: Standard of Care; Radiation: SBRT
Sponsors: Dana-Farber Cancer Institute; Adenoid Cystic Carcinoma Research Foundation; Gateway for Cancer Research
Recruiting
-
Posted: January 22nd, 2021, 1:00am UTC
Conditions:
Relapsed
Solid
Tumors;
Refractory
Solid
Tumors;
Non-Hodgkin
Lymphoma;
HGSOC;
Platinum
Resistant
High
Grade
Serous
Ovarian
Cancer
Interventions:
Drug:
KB-0742
Sponsors:
Kronos
Bio
Active,
not
recruiting
-
Posted: January 31st, 2020, 1:00am UTC
Conditions: Prostatic Neoplasms, Castration-Resistant; Neoplasms by Histologic Type; Neoplasms, Prostate; Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Neoplasms; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Prostatic Disease; Salivary Gland Cancer; Salivary Gland Tumor; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma; Mucoepidermoid Carcinoma; Acinic Cell Tumor
Interventions: Biological: P-PSMA-101 CAR-T cells; Drug: Rimiducid
Sponsors: Poseida Therapeutics, Inc.
Active, not recruiting
-
Posted: December 24th, 2019, 1:00am UTC
Conditions: Adenoid Cystic Carcinoma; Salivary Gland Cancer
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC; Eisai Inc.
Active, not recruiting
-
Posted: October 28th, 2019, 11:00pm UTC
Conditions: Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma
Interventions: Drug: ONC-392; Drug: Pembrolizumab; Drug: Docetaxel
Sponsors: OncoC4, Inc.; National Cancer Institute (NCI)
Recruiting
-
Posted: October 8th, 2019, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: Rivoceranib
Sponsors: Elevar Therapeutics
Terminated
-
Posted: June 19th, 2019, 11:00pm UTC
Conditions: Metastatic Adenoid Cystic Carcinoma; Progressive Disease; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: Avelumab; Drug: Axitinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Completed
-
Posted: December 20th, 2018, 1:00am UTC
Conditions: Malignant Salivary Gland Cancer; Salivary Gland Cancer
Interventions: Drug: APG-115; Drug: Carboplatin
Sponsors: University of Michigan Rogel Cancer Center; Ascentage Pharma Group Inc.
Active, not recruiting
-
Posted: October 1st, 2018, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: AL101
Sponsors: Ayala Pharmaceuticals, Inc,
Completed
-
Posted: September 7th, 2018, 11:00pm UTC
Conditions: Particle Therapy
Interventions: Radiation: carbon ions radiation therapy; Radiation: protons radiation therapy
Sponsors: CNAO National Center of Oncological Hadrontherapy
Recruiting
-
Posted: June 14th, 2018, 11:00pm UTC
Conditions: Head and Neck Carcinoma; Adenoid Cystic Carcinoma; Lung Cancer; Non-Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer; Mesothelioma; Thymic Carcinoma; Cervical Cancer; Ovarian Cancer; Bladder Cancer; Esophageal Cancer; Uterine Cancer; Sarcoma; Any Solid Tumors Progressed After a Prior Immunotherapy; Thymoma; Appendiceal Cancer; Olfactory Neuroblastoma
Interventions: Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
Sponsors: VM Oncology, LLC
Recruiting
-
Posted: February 6th, 2018, 1:00am UTC
Conditions: Breast Cancer; Colorectal Cancer; Adenoid Cystic Carcinoma; Non-hodgkin Lymphoma; Glomus Tumor, Malignant; Hepatocellular Carcinoma; Osteosarcoma; T-ALL
Interventions: Drug: CB-103
Sponsors: Cellestia Biotech AG
Terminated
-
Posted: June 1st, 2017, 11:00pm UTC
Conditions: Salivary Gland Cancer
Interventions: Drug: Nivolumab; Drug: Ipilimumab
Sponsors: Memorial Sloan Kettering Cancer Center; Bristol-Myers Squibb
Active, not recruiting
-
Posted: May 10th, 2017, 11:00pm UTC
Conditions: Major Salivary Gland Carcinoma; Minor Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVC Major Salivary Gland Carcinoma
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab
Sponsors: Northwestern University; Bristol-Myers Squibb; National Cancer Institute (NCI)
Active, not recruiting
-
Posted: December 1st, 2016, 1:00am UTC
Conditions: Adnexal Carcinoma; Anaplastic Large Cell Lymphoma, ALK-Negative; Anaplastic Large Cell Lymphoma, ALK-Positive; Apocrine Carcinoma; Carcinoma Arising From Cylindroma; Carcinoma Arising From Spiradenoma; Digital Papillary Adenocarcinoma; Endocrine Mucin-Producing Sweat Gland Carcinoma; Extramammary Paget Disease; Extraocular Sebaceous Carcinoma; Hidradenocarcinoma; Keratoacanthoma; Malignant Sweat Gland Neoplasm; Merkel Cell Carcinoma; Microcystic Adnexal Carcinoma; NK-Cell Lymphoma, Unclassifiable; Papillary Adenocarcinoma; Porocarcinoma; Primary Cutaneous Mucinous Carcinoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Merkel Cell Carcinoma; Refractory Mycosis Fungoides; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Skin Squamous Cell Carcinoma; Refractory T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; Signet Ring Cell Adenocarcinoma; Skin Adenoid Cystic Carcinoma; Skin Basal Cell Carcinoma; Skin Basosquamous Cell Carcinoma; Skin Squamous Cell Carcinoma; Squamoid Eccrine Ductal Carcinoma; Squamous Cell Carcinoma of Unknown Primary; Sweat Gland Carcinoma; Trichilemmal Carcinoma; Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Procedure: Positron Emission Mammography; Biological: Talimogene Laherparepvec
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: August 8th, 2016, 11:00pm UTC
Conditions: Recurrent ACC, metastaticACC, Unreaectable ACC
Interventions: Drug: Axitinib; Other: Observation
Sponsors: Seoul National University Hospital
Completed
-
Posted: July 15th, 2016, 11:00pm UTC
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Neuroendocrine Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Low Grade Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Penile Squamous Cell Carcinoma; Peritoneal Mesothelial Neoplasm; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Echocardiography; Biological: Ipilimumab; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: May 26th, 2016, 11:00pm UTC
Conditions: Neoplasms
Interventions: Drug: GSK3326595; Drug: Pembrolizumab
Sponsors: GlaxoSmithKline
Completed
-
Posted: May 23rd, 2016, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: Lenvatinib
Sponsors: Memorial Sloan Kettering Cancer Center; Eisai Inc.
Active, not recruiting
-
Posted: March 28th, 2014, 11:00pm UTC
Conditions:
Adenoid
Cystic
Carcinoma
Interventions:
Drug:
Regorafenib
Sponsors:
Memorial
Sloan
Kettering
Cancer
Center;
Bayer
Completed
-
Posted: May 12th, 2009, 11:00pm UTC
Conditions: Head and Neck Cancer
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Vanderbilt University Medical Center; National Cancer Institute (NCI)
Recruiting